Acro Biomedical (ACBM) Equity Ratio (2015 - 2025)

Acro Biomedical's Equity Ratio history runs 11 years deep, the most recent figure standing at 27.45 for Q4 2025.

• In Q4 2025, Equity Ratio fell 197.53% year-over-year to 27.45; the TTM figure through Dec 2025 stood at 27.45 (down 197.53% YoY), while the FY2025 annual figure was 27.45, down 197.53% from the prior year.
• Equity Ratio was 27.45 for Q4 2025 at Acro Biomedical, up from 100.07 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.91 in Q2 2021 to a low of 100.07 in Q3 2025.
• Historically, Equity Ratio has averaged 9.14 across 5 years, with a median of 1.89 in 2023.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio tumbled 1746.94% in 2023, then soared 41.38% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.85 in 2021, then declined by 16.35% to 0.71 in 2022, then sank by 721.44% to 4.4 in 2023, then sank by 109.84% to 9.23 in 2024, then sank by 197.53% to 27.45 in 2025.
• The last three Equity Ratio figures came in at 27.45 (Q4 2025), 100.07 (Q3 2025), and 5.96 (Q2 2025), per Business Quant data.